Four JAK Inhibitors Have Comparable Efficacy, Safety for RA

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 1, 2023.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 1, 2023 -- For patients with rheumatoid arthritis, the efficacy and safety of four Janus kinase (JAK) inhibitors is comparable, according to a study published online Nov. 1 in Rheumatology.

Shinya Hayashi, M.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues conducted a multicenter, retrospective study comparing the efficacy and safety of tofacitinib (TOFA), baricitinib (BARI), peficitinib, and upadacitinib in 622 patients in real-world clinical settings. In the four treatment groups, patient backgrounds were matched using propensity score-based inverse probability of treatment weighting.

The researchers found that among the four JAK inhibitor groups, the retention and discontinuation rates until six months after drug initiation did not differ significantly. Furthermore, no differences were seen in mean Clinical Disease Activity Index (CDAI) value, CDAI remission rate, or CDAI-low disease activity (LDA) rate at six months after drug initiation. Predictive factors for resistance to CDAI-LDA achievement for JAK inhibitor treatment included baseline CDAI (odds ratios, 1.09 for tofacitinib and 1.07 for baricitinib), baseline C-reactive protein (CRP; odds ratio, 1.32 for tofacitinib), baseline glucocorticoid dose (odds ratio, 1.18 for baricitinib), and number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs; odds ratio, 1.36 for baricitinib).

"Baseline CRP titer and CDAI were identified as predictive factors for resistance to LDA achievement with TOFA," the authors write. "Baseline glucocorticoid dose, baseline CDAI, and number of previous b/tsDMARDs were identified as the predictive factors with BARI."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-02 02:34

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords